2.77
price down icon9.77%   -0.30
after-market Handel nachbörslich: 2.86 0.09 +3.25%
loading
Schlusskurs vom Vortag:
$3.07
Offen:
$3.04
24-Stunden-Volumen:
476.21K
Relative Volume:
1.45
Marktkapitalisierung:
$155.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.66M
KGV:
-0.8946
EPS:
-3.0963
Netto-Cashflow:
$-97.76M
1W Leistung:
-13.17%
1M Leistung:
+8.63%
6M Leistung:
-25.94%
1J Leistung:
-64.53%
1-Tages-Spanne:
Value
$2.755
$3.04
1-Wochen-Bereich:
Value
$2.755
$3.75
52-Wochen-Spanne:
Value
$1.78
$11.40

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name
Firmenname
Kyverna Therapeutics Inc
Name
Telefon
(510) 626-8331
Name
Adresse
5980 HORTON STREET, EMERYVILLE
Name
Mitarbeiter
119
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
KYTX's Discussions on Twitter

Vergleichen Sie KYTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KYTX
Kyverna Therapeutics Inc
2.77 155.59M 0 -110.66M -97.76M -3.0963
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-27 Hochstufung H.C. Wainwright Neutral → Buy
2024-10-10 Eingeleitet UBS Buy
2024-10-09 Eingeleitet Rodman & Renshaw Buy
2024-07-03 Eingeleitet H.C. Wainwright Neutral
2024-03-04 Eingeleitet JP Morgan Overweight
2024-03-04 Eingeleitet Leerink Partners Outperform
2024-03-04 Eingeleitet Morgan Stanley Overweight
2024-03-04 Eingeleitet Wells Fargo Overweight
Alle ansehen

Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten

pulisher
Jun 18, 2025

Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineKYTX - ACCESS Newswire

Jun 18, 2025
pulisher
Jun 17, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $18.50 Average Target Price from Analysts - MarketBeat

Jun 17, 2025
pulisher
Jun 12, 2025

Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech

Jun 12, 2025
pulisher
Jun 12, 2025

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - marketscreener.com

Jun 12, 2025
pulisher
Jun 10, 2025

3 Promising Penny Stocks With Market Caps Over $100M - Yahoo Finance

Jun 10, 2025
pulisher
Jun 07, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Sees Large Increase in Short Interest - MarketBeat

Jun 07, 2025
pulisher
Jun 06, 2025

Lead Plaintiff Appointed in Kyverna Class Action — Here’s How You Can Recover Your Losses - TradingView

Jun 06, 2025
pulisher
Jun 06, 2025

KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 05, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 04, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Millennium Management LLC - MarketBeat

Jun 04, 2025
pulisher
Jun 03, 2025

Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 4,990 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Raises Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace

Jun 02, 2025
pulisher
May 31, 2025

Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts - MSN

May 31, 2025
pulisher
May 31, 2025

Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire

May 31, 2025
pulisher
May 31, 2025

BNP Paribas Financial Markets Purchases 17,786 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

May 31, 2025
pulisher
May 31, 2025

Northern Trust Corp Purchases 61,757 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

May 31, 2025
pulisher
May 31, 2025

Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Buy" at HC Wainwright - MarketBeat

May 31, 2025
pulisher
May 28, 2025

Kyverna Therapeutics to Present at the Jefferies Global Healthca - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference - PR Newswire

May 28, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 28, 2025

Kyverna Therapeutics’ KYV-101: Promising Developments and First-to-Market Potential in Autoimmune Diseases - TipRanks

May 28, 2025
pulisher
May 28, 2025

Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to “Buy” at HC Wainwright - Defense World

May 28, 2025
pulisher
May 27, 2025

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga

May 27, 2025
pulisher
May 27, 2025

Kyverna Therapeutics Shares Rise After Upgrade From HC Wainwright - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

HC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX) - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Kyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position - TipRanks

May 27, 2025
pulisher
May 27, 2025

HC Wainwright Upgrades Kyverna Therapeutics to Buy From Neutral, Adjusts Price Target to $5 From $4 - marketscreener.com

May 27, 2025
pulisher
May 26, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

May 26, 2025
pulisher
May 26, 2025

HC Wainwright Issues Pessimistic Estimate for KYTX Earnings - MarketBeat

May 26, 2025
pulisher
May 25, 2025

Analysts Offer Predictions for KYTX Q1 Earnings - MarketBeat

May 25, 2025
pulisher
May 22, 2025

HC Wainwright Issues Pessimistic Outlook for KYTX Earnings - Defense World

May 22, 2025
pulisher
May 22, 2025

Analysts Issue Forecasts for KYTX Q1 Earnings - Defense World

May 22, 2025
pulisher
May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025
pulisher
May 21, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of “Buy” by Analysts - Defense World

May 21, 2025
pulisher
May 20, 2025

Jacobs Levy Equity Management Inc. Buys 442,090 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

May 20, 2025
pulisher
May 18, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Sphera Funds Management LTD. - MarketBeat

May 18, 2025
pulisher
May 17, 2025

Integral Health Asset Management LLC Purchases 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

May 17, 2025
pulisher
May 17, 2025

Leerink Partnrs Has Positive Outlook of KYTX Q2 Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

Stifel Financial Corp Buys New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

May 16, 2025
pulisher
May 16, 2025

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive

May 16, 2025
pulisher
May 15, 2025

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Kyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPO - Bloomberg Law News

May 15, 2025
pulisher
May 15, 2025

Kyverna planning to launch Phase 3 trial of KYV-101 in MG patients - Myasthenia Gravis News

May 15, 2025
pulisher
May 15, 2025

With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors - Yahoo Finance

May 15, 2025

Finanzdaten der Kyverna Therapeutics Inc-Aktie (KYTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):